Medical Therapy. Efficacy or Lack of Efficacy

Updates in the Treatment of Pediatric Pulmonary Arterial Hypertension

Danya Z. Jafri, James M. Beck, Samantha A. Kaplan, Allegra Keeler, Bryan Sanchez, Daniela Brady, William H. Frishman, Wilbert S. Aronow, Avi Levine, Erika Rosenzweig, Gregg M. LanierNew York Medical College School of Medicine. Westchester Medical Center.United States Cardiology in ReviewCardiol Rev 2026; DOI: 10.1097/CRD.0000000000001239 AbstractPediatric pulmonary arterial hypertension (PAH) is a relentless and potentially fatal […]

Updates in the Treatment of Pediatric Pulmonary Arterial Hypertension Read More »

Neonatal pulmonary vascular remodeling induced by increased blood flow is associated with an antiviral-like immune signature

Sixie Zheng, Hao Li, Siqi She, Yiting Xue, Debao Li, Jiapei Wang, Jing Wang, Yuqing Hu, Lincai YeShanghai Children’s Medical Center and Shanghai Jiao Tong University School of Medicine. Children’s Hospital of Fudan University and National Children’s Medical Center. Affiliated Women and Children’s Hospital of Ningbo University. China Frontiers in ImmunologyFront Immunol 2026; 17: DOI: 10.3389/fimmu.2026.1780303

Neonatal pulmonary vascular remodeling induced by increased blood flow is associated with an antiviral-like immune signature Read More »

Pulmonary Hypertension Associated With Vitamin C Deficiency Is Rapidly Reversible

Tomás Woodgate, Jay Patel, Thomas Day, Brodie Knight, Adriani Spanaki, Alistair Calder, Shahin Moledina, Sadia QuyamGreat Ormond Street Hospital. Royal Hospital for Children. Evelina London Children’s Hospital,United Kingdom PediatricsPediatrics 2026; DOI: 10.1542/peds.2025-073645 AbstractWe report 4 children (aged 3-9 years) with severe pulmonary hypertension (PH) associated with vitamin C deficiency. All presented with either musculoskeletal symptoms or

Pulmonary Hypertension Associated With Vitamin C Deficiency Is Rapidly Reversible Read More »

Protocol for an open-label, randomised, controlled trial to evaluate the efficacy and safety of sotatercept add-on therapy compared with pulmonary vasodilator-based standard of care for pulmonary vasodilator-resistant pulmonary arterial hypertension associated with unrepaired congenital shunts (atrial septal defect, ventricular septal defect or patent ductus arteriosus), including Eisenmenger syndrome: the SuMILE trial

Keimei Yoshida, Kazuya Hosokawa, Takahiro Hiraide, Satoshi Akagi, Kentaro Ejiri, Yu Taniguchi, Shiro Adachi, Takumi Inami, Naohiko Nakanishi, Masaharu Kataoka, Taijyu Satoh, Shunsuke Tatebe, Toshiro Shinke, Hideshi Tomita, Yusuke Akazawa, Takashi Higaki, Koshiro Tagawa, Ayako Ishikita, Soshun Asakawa, Kohtaro AbeKyushu University and Kyushu University Hospital. Keio University School of Medicine. Okayama University. Kobe University Hospital.

Protocol for an open-label, randomised, controlled trial to evaluate the efficacy and safety of sotatercept add-on therapy compared with pulmonary vasodilator-based standard of care for pulmonary vasodilator-resistant pulmonary arterial hypertension associated with unrepaired congenital shunts (atrial septal defect, ventricular septal defect or patent ductus arteriosus), including Eisenmenger syndrome: the SuMILE trial Read More »

Sotatercept in Patients With Eisenmenger Syndrome

Oktay Tutarel, Oliver Miera, Felix BergerDeutsches Herzzentrum der Charité, Freie Universität Berlin and Humboldt-Universität zu Berlin.Germany Pulmonary CirculationPulm Circ 2026; 16: DOI: 10.1002/pul2.70283 AbstractEisenmenger syndrome represents a complex and severe form of pulmonary arterial hypertension (PAH) associated with congenital heart disease. Sotatercept, a first-in-class activin-signaling inhibitor, offers a novel therapeutic approach in the treatment of PAH,

Sotatercept in Patients With Eisenmenger Syndrome Read More »

Reversing the irreversible? A case of successful surgical repair in a late-presenting aortopulmonary window with severe pulmonary hypertension

Rido Mulawarman, Ericko Ongko Joyo, Muhamad Adrin Aefiansyah Putra, Aditya Agita Sembiring, Sisca Natalia Siagian, Oktavia LilyasarUniversitas Indonesia. Indonesia Egyptian Heart JournalEgypt Heart J 2026; 78: DOI: 10.1186/s43044-026-00726-7 AbstractBackground: Aortopulmonary window (APW) is a rare congenital heart defect, accounting for only 0.2-0.6% of all congenital cardiac anomalies, and is usually identified and surgically corrected within the first

Reversing the irreversible? A case of successful surgical repair in a late-presenting aortopulmonary window with severe pulmonary hypertension Read More »

Macitentan vs Standard of Care in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial

Rolf M. F. Berger, D. Dunbar Ivy, Julian I. Borissoff, Sofija Cerovic, Dénes Csonka, Tatiana Remenová, Dominik Richard, Matthieu Villeneuve, Maurice BeghettiBeatrix Children’s Hospital, University Medical Center Groningen and University of Groningen. Children’s Hospital Colorado. Johnson & Johnson. University Hospitals of Geneva.Netherlands, United States and Switzerland Journal of PediatricsJ Pediatr 2026; DOI: 10.1016/j.jpeds.2026.115057 AbstractObjectives: To evaluate pharmacokinetics

Macitentan vs Standard of Care in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial Read More »

Hypercapnia as a Key Mechanism in the Development of Pulmonary Hypertension in Malignant Pertussis: A Case Report

Juan Ignacio Muñoz-Bonet, Francisco José Sebastián-Cuevas, Eva María Flor-Macián, María del Carmen Ortega-Sánchez, Andrés Rodríguez-Sacristán, Juan BrinesHospital Clínico Universitario. University of Valencia. Hospital Dr. Peset Valencia. Hospital Universitario Virgen Macarena.Spain Respirology Case ReportsRespirol Case Rep 2026; 14: DOI: 10.1002/rcr2.70528 AbstractMalignant pertussis (MP) is a highly lethal complication of pertussis in young infants, typically associated with hyperleukocytosis, pulmonary

Hypercapnia as a Key Mechanism in the Development of Pulmonary Hypertension in Malignant Pertussis: A Case Report Read More »

Lamp Oil Poisoning: Pulmonary Hypertension Following Oil Aspiration Successfully Treated with Inhaled Nitric Oxide

Demet Tosun, Ilyas Bingöl Nihal AkçayIstanbul Kanuni Sultan Suleyman Training and Research Hospital.Turkey Klinische PädiatrieKlin Padiatr 2026; DOI: 10.1055/a-2814-3185 AbstractAbstract Not Available CategoryClass I. Drug-induced and Toxin-induced Pulmonary HypertensionMedical Therapy. Efficacy or Lack of Efficacy Age Focus: Pediatric Pulmonary Vascular Disease Fresh or Filed Publication: Fresh (PHresh). Less than 1-2 years since publication Article Access Free

Lamp Oil Poisoning: Pulmonary Hypertension Following Oil Aspiration Successfully Treated with Inhaled Nitric Oxide Read More »

Clinical Application of Inhaled Nitric Oxide in Conditions of Excessive Right Heart Load: A Review from Neonatal Pulmonary Hypertension to Perioperative Cardiac Surgery Management

Chengming Hu, Zhe Chen, Lizhi Lv, Yan Zhu, Yan Chen, Qiang WangBeijing Anzhen Hospital and Capital Medical University.China Journal of Cardiovascular Development and DiseaseJ Cardiovasc Drv Dis 2026; 13: DOI: 10.3390/jcdd13020081 AbstractExcessive right heart load imposes an acute or chronic injury on the right ventricle (RV), predisposing critically ill neonates and cardiac surgical patients to RV

Clinical Application of Inhaled Nitric Oxide in Conditions of Excessive Right Heart Load: A Review from Neonatal Pulmonary Hypertension to Perioperative Cardiac Surgery Management Read More »

Scroll to Top